We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke possibly due to semaglutide-related blood clots. Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active … More
Main Navigation Menu
➤ Current Drug Injury Lawsuits / Pharmaceutical Litigations
➤ Drug Injury Case Evaluation – Free. Confidential. No Obligation.
➤ Information About the Law Offices of Thomas J. Lamb
➤ Questions New Clients Have Asked Us (FAQs)
➤ Patient Resources: Medical Sites and More
➤ Recent Side Effects Blog Articles
➤ Collection of Earlier Blog Articles
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Case Reports
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide -- the active ingredient in Ozempic as well as Wegovy and Rybelsus. … More
Syfovre’s Risks Keep It Off The Market In Europe, Again, With June 2024 Decision
As we have been reporting since July 2023, Syfovre's risks include serious eye side effects such as occlusive retinal vasculitis, a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive … More
Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving a stroke, pulmonary embolism, or deep vein thrombosis when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and … More
Syfovre: Loss of Vision 11 Days After Receiving Syfovre Injection
This blog post is about a Syfovre loss of vision case involving a 78-year-old woman with vision loss in the first part of 2023. It was reported in this medical journal article, "Retinal vasculitis following intravitreal pegcetacoplan administration", which appeared in the March 2024 edition of the … More
Syfovre Eye Injury Cases Update One Year After First Reports: “Uncertain”
Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that both the etiology and the incidence rate of retinal vasculitis after … More